-7%

Forcyl swine 160 mg/ml Solution for Injection for pigs

Original price was: $70.00.Current price is: $65.00.

Forcyl swine 160 mg/ml Solution for Injection for pigs
Species: Pigs
Therapeutic indication: Pharmaceuticals: Antimicrobials: Injections
Active ingredient: Marbofloxacin
Product: Forcyl swine 160 mg/ml Solution for Injection for pigs
Product index: Forcyl Swine
Pig – meat: Meat and offal: 9 days
Category:

Buy Forcyl swine 160 mg/ml Solution for Injection for pigs Online

We are pleased to introduce you to our exceptional product, “Forcyl Swine 160 mg/ml Solution for Injection” specially designed for pigs.

Product Name: Forcyl Swine 160 mg/ml Solution for Injection
Active Ingredient: Each milliliter of Forcyl Swine contains 160 mg of the active ingredient (to be specified if available)

Product Description:
Forcyl Swine 160 mg/ml Solution for Injection is a premium veterinary medication specifically formulated to address the health needs of pigs. This injectable solution provides effective treatment and prevention of various bacterial infections, promoting the well-being and productivity of swine populations.

Key Features and Benefits:

  1. Broad-Spectrum Antibiotic: Forcyl Swine contains a potent broad-spectrum antibiotic that tackles a wide range of bacterial pathogens commonly affecting pigs. It helps combat infections and supports the recovery process.
  2. High Efficacy: The active ingredient in Forcyl Swine has been carefully selected for its proven efficacy against specific bacterial strains prevalent in swine populations. It provides reliable and consistent results in treating and preventing infections.
  3. Veterinary Approved: Forcyl Swine is developed in accordance with the highest veterinary standards. It is manufactured by reputable companies and undergoes rigorous quality control measures to ensure safety, purity, and compliance with regulatory requirements.
  4. Convenient Administration: The solution is designed for easy and convenient administration. It allows for accurate dosage calculation and precise injection, ensuring optimal therapeutic outcomes.
  5. Enhanced Animal Welfare: By effectively addressing bacterial infections, Forcyl Swine contributes to the overall health and welfare of pigs. It helps to minimize discomfort, reduce morbidity rates, and support the growth and productivity of swine populations.

Usage Instructions:
Forcyl Swine 160 mg/ml Solution for Injection should be administered by a qualified veterinarian or under their guidance. The dosage and administration regimen may vary depending on the specific condition and the veterinarian’s prescription. It is crucial to follow the instructions provided by the veterinarian for accurate dosage and proper administration.

Please note that Forcyl Swine is intended for use in pigs only and should not be used in other animal species or humans.

Ordering Information:
To order Forcyl Swine 160 mg/ml Solution for Injection or inquire about pricing and shipping options, please visit our secure website at www.equicurepharm.com. Our dedicated customer support team is available to assist you with any queries or concerns you may have.

Disclaimer:
Forcyl Swine 160 mg/ml Solution for Injection is a veterinary medication and should be used strictly as directed by a qualified veterinarian. Equicurepharm assumes no liability for the misuse or improper administration of Forcyl Swine.

At Equicurepharm, we are committed to the health and welfare of animals. Trust Forcyl Swine for effective bacterial infection management in pigs and experience the positive impact it can have on swine populations.

Forcyl swine 160 mg/ml Solution for Injection for pigs Species: Pigs

 

Therapeutic indication: Pharmaceuticals: Antimicrobials: Injections
Active ingredient: Marbofloxacin
Product: Forcyl swine 160 mg/ml Solution for Injection for pigs
Product index: Forcyl Swine
Pig – meat: Meat and offal: 9 days
Presentation
Solution for injection. Clear yellow greenish to yellow brownish solution. One ml contains 160 mg marbofloxacin and 15 mg benzyl alcohol.
Uses
In fattening pigs: Treatment of respiratory tract infections caused by susceptible strains of Actinobacillus pleuropneumoniae and Pasteurella multocida. In weaned piglets: Treatment of intestinal infections caused by susceptible strains of E. coli. In post-partum sows: Treatment of metritis mastitis agalactia syndrome (form of postpartum dysgalactiae syndrome, PPDS) caused by susceptible strains of E. coli.
Dosage and administration
The recommended dosage is 8 mg/kg body weight i.e. 1 ml/20 kg body weight in a single intramuscular injection in the side of the pig neck. To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid underdosing.
Contra-indications, warnings, etc
Do not use in animals with known hypersensitivity to fluoroquinolones or to any of the excipients. To limit development of resistance, do not use fluoroquinolones as prophylaxis or metaphylaxis to prevent diarrhoea at weaning.
Special warnings
Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).
Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when this product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Wherever possible, use of the product should only be based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to (fluoro)quinolones and benzyl alcohol should avoid any contact with the product. Wash hands after use. Avoid contact of the skin and eyes with the product. If the product comes into contact with the skin or eyes, rinse with copious amounts of water. Care should be taken to avoid accidental self-injection. In the event of accidental self-administration, the user should immediately seek professional medical care. Accidental self-injection can induce a slight irritation.
Adverse reactions (frequency and seriousness)
Local reactions can be observed at the injection site, which disappear within 36 days.
Pain at the injection site has been commonly reported (more than 1 but less than 10 animals in 100 animals).
Use during pregnancy, lactation or lay
Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic, embryotoxic or maternotoxic effect associated with the use of marbofloxacin. The safety of the veterinary medicinal product has not been established at 8 mg/kg in pregnant sows or in suckling piglets when used in sows. Use only according to the benefit/risk assessment carried out by the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction
None known
Overdose (symptoms), emergency procedures, antidotes), if necessary
Lesions of the joint cartilage, potentially leading to difficulties in movement, were observed in some animals treated at three times the recommended dose and treatment duration.
Withdrawal period
Meat and offal: 9 days
Incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
Pharmaceutical precautions
Shelf life of the veterinary medicinal product as packaged for sale: 3 years Shelf life after first opening the immediate packaging: 28 days.
This veterinary medicinal product does not require any special storage conditions.
Packaging quantities
Cardboard box containing one 50 ml vial.
Further information
Pharmacotherapeutic group: antibacterials for systemic use
Pharmacodynamic properties
Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group, which acts by inhibition of DNA gyrase. It has a broad-spectrum activity in vitro against Gram-positive bacteria and Gram-negative bacteria. Between 2009 and 2013, the activity of marbofloxacin against Pasteurella multocida (n=444) and Escherichia coli (n= 1226) isolated from swine diseases in Europe was for P. multocida: MIC range: 0.004-1 μg/ml, MIC50: 0.013µg/ml MIC90: 0.028μg/ml, for E. coli (digestive infections): MIC range 0.008-64µg/ml; MIC50:0.026µg/ml; MIC90:0.681µg/ml, for E. coli (MMA syndrome): MIC range 0.015-16µg/ml; MIC50:0.024µg/ml; MIC90:0.475µg/ml. Marbofloxacin MIC distribution among E. coli strains isolated from digestive or MMA syndrome are similar with a trimodal distribution.
The clinical breakpoints defined for marbofloxacin are S ≤ 1 µg/mL, I = 2 µg/mL and R ≥ 4 µg/mL for Pasteurellaceae according to the “Comité de l’Antibiogramme de la Société Française de Microbiologie” (=French Society of Microbiology) (CA-SFM 2013).
Between 2009 and 2012, the activity of marbofloxacin against Actinobacillus pleuropneumoniae (n=157) isolated from swine diseases in Europe was: MIC range: 0.015-2µg/mL, MIC50: 0.03µg/mL, MIC90: 0.06µg/mL
The activity of marbofloxacin against the target bacterial species is bactericidal concentration-dependent. A decrease of susceptibility of Campylobacter spp. against fluoroquinolones was observed since 1999.
Resistance to fluoroquinolones occurs by chromosomal mutation with three mechanisms: decrease of the bacterial wall permeability, expression of efflux pump or mutation of enzymes responsible for molecule binding. To date, only sporadic cases have been reported for plasmid mediated fluoroquinolone resistance in animals. Depending on the underlying resistance mechanism cross-resistance to other (fluoro)quinolones and co-resistance to other antimicrobial classes can occur.
Pharmacokinetic particulars
After administration of an intramuscular dose of 8 mg/kg, the following mean pharmacokinetic parameters were observed:
Marbofloxacin is extensively distributed. Uterus tissue concentrations in sows reach Cmax of 9.346 µg/g in the uterine body observed at Tmax of 1.00 h after administration and the AUC last was 105.4 µg.h/g. Binding to plasma proteins is weak, about 4%. In pigs, the elimination is predominantly as the active form in urine and faeces.
In the studies performed, marbofloxacin was eliminated slightly faster in post-weaning piglets than in heavier animals.

Reviews

There are no reviews yet.

Be the first to review “Forcyl swine 160 mg/ml Solution for Injection for pigs”

Related products

Quick View

 Injectable 

17 KOLIK EAZ INJ

$40.00
Add to cart
Quick View

 Injectable 

Adenosine Monophosphate Injection (AMP)

$40.00
Add to cart
-13%
Quick View

 Injectable 

ACEPROMAZINE

Original price was: $40.00.Current price is: $35.00.
Add to cart
Quick View

 Injectable 

Adequan i.m

$45.00
Add to cart
-20%
Quick View

 Injectable 

12p15 10ml

Original price was: $50.00.Current price is: $40.00.
Add to cart
Quick View

 Injectable 

Ace-C 200

$35.00
Add to cart
-14%
Quick View

 Injectable 

ACS LTF

Original price was: $35.00.Current price is: $30.00.
Add to cart
-16%
Quick View

 Injectable 

Adequan Canine 2 x 5ml

Original price was: $125.00.Current price is: $105.00.
Add to cart